Chardan Capital Reiterates Buy Rating for Tenax Therapeutics
Chardan Capital maintains its optimistic outlook on Tenax Therapeutics with a reiterated buy rating, a 108.82% upside from the current price.
Key Points
- Chardan Capital reiterated its buy rating for Tenax Therapeutics (TENX) on June 22, 2026, with a price target of $27.
- Chardan Capital's $27 price target implies 108.82% upside from Tenax Therapeutics, Inc.'s ($TENX) current $12.93 share price.
- Shares of TENX traded at $12.00 on Monday, with a market cap of $318.3 million and a 52-week range between $5.62 and $18.38.
- Recent insider activity includes significant stock purchases by company executives, with no insider selling reported.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Chardan Capital has reiterated its buy rating for Tenax Therapeutics, Inc. (NASDAQCM:TENX) on June 22, 2026. The firm, represented by analyst Gautam Chukka, set a price target of $27 for the pharmaceutical company.
Tenax Therapeutics, Inc. Stock Up 507.0%
Shares of NasdaqCM:TENX traded near $12.00 on Monday. Tenax Therapeutics boasts a market cap of approximately $318.3 million. The company is currently not profitable, with no meaningful P/E ratio, but has a forward P/E of -8.5. The stock has seen a 52-week low of $5.62 and a high of $18.38. The 50-day moving average is $12.47, while the 200-day moving average stands at $11.05. Tenax has a strong liquidity position, with a current ratio of 14.5 and a quick ratio of 14.0.
$TENX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Tenax Therapeutics is yet to report positive earnings. The company's EPS stands at -$1.41, and it has a return on equity of -51.7%. The next earnings report is expected on August 11, 2025.
Insider Buying and Selling at Tenax Therapeutics, Inc.
Recent insider activity at Tenax Therapeutics shows significant buying. On May 11, 2026, Chief Financial Officer Thomas Staab II acquired 450,000 shares. Earlier in the year, interim CFO Thomas McGauley bought 50,000 shares on January 30, 2026. Notably, all insider transactions were purchases, indicating confidence in the company's prospects.
Analysts Set New Price Targets
Chardan Capital reiterated its buy rating with a $27 price target on June 22, 2026. Piper Sandler maintained its buy rating with a target of $50 on June 12, 2026. Cantor Fitzgerald initiated coverage with a buy rating and a $35 target on March 17, 2026. Overall, the consensus among seven analysts is a strong buy, with a mean target price of $34.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina. It focuses on developing novel therapies for cardiopulmonary diseases. The company is working on several treatments, including TNX-101, TNX-102, and TNX-103, which are in phase II trials for pulmonary hypertension. Tenax was founded in 1967 and is led by CEO Christopher T. Giordano.
Bottom Line
Chardan Capital's reiterated buy rating and $27 price target reflect continued confidence in Tenax Therapeutics' potential. Investors often track analyst ratings as a gauge of market sentiment. It's important to remember that these ratings are based on past information and may not represent future performance.
Get Tenax Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TENX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.